Dyskeratosis congenita (DC) is a congenital bone marrow failure (BMF) disorder characterized by abnormal skin pigmentation, nail dystrophy, oral leukoplakia and cancer predisposition. 1 Tissue-specific pathologies arise in DC due to the presence of critically short telomeres, often in cells with higher replicative capacities. The most commonly mutated gene in DC is DKC1 encoding dyskerin, located on the long arm of the X-chromosome, and is generally considered to manifest a more severe phenotype. 1 Pulmonary disease is common in DC and includes abnormal pulmonary vasculature or pulmonary fibrosis.
1,2
Pulmonary decline may present early in life, usually after the onset of BMF, 3 or later in life with or without typical hematologic or mucocutaneous findings. 4 The high incidence of pulmonary disease/complications post hematopoietic stem cell transplant (HSCT) in DC patients suggests an underlying predisposition to lung injury. Furthermore, HSCT-related morbidity may be related to an underlying sensitivity to cytotoxic agents due to aberrant cellular DNA damage repair and dysregulated reactive oxidative species. 5 Reduced-intensity conditioning (RIC) HSCT preparative regimens have been employed with variable success. 6, 7 Here we describe an adolescent DC patient with a history of respiratory disease, who underwent a RIC HSCT and subsequently developed fatal pulmonary complications. Collection of lung tissue postmortem provided an opportunity to more fully characterize the molecular consequences of defective telomerase in a disease-specific target organ. Our patient presented to the Hematology Service at 1 year of age for isolated macrocytic anemia. Within 3 years he developed mild thrombocytopenia with dyskeratotic nail changes. Gene testing revealed a pathogenic DKC1 mutation (A353V), and over the following 10 years he developed esophageal and urethral strictures, retinal hemorrhages and osteopenia. At 10 years of age, Danazol therapy was initiated for worsening pancytopenia, but was discontinued after 5 years with concerns of hepatic toxicity. HSCT referral was made due to imminent transfusion dependency. Pre-HSCT workup demonstrated a hypocellular marrow (5-10%) without myelodysplastic features. He had been followed by the Pulmonary Service since 8 years of age for asthma-like symptoms and was prescribed inhaled bronchodilators. Chest CT scan revealed pulmonary blebs. Pulmonary function testing (PFT), starting at 10 years of age, showed a progressive decline in diffusing capacity for carbon monoxide (DLCO), from 95-75% by age 17.
The patient underwent HSCT using matched sibling bone marrow as per a previously published RIC preparative regimen (fludarabine 40 mg/m 2 × 5 days, cyclophosphamide 50 mg/kg × 1 day, alemtuzumab 0.2 mg/kg × 5 days and total body irradiation 200 cGy). 7 The patient attained 100% donor engraftment by day 60, which persisted throughout transplant. Post-HSCT complications during the first 180 days included hemorrhagic cystitis, appendicitis, Candida esophagitis and CMV reactivation. He had persistent Coombs-positive hemolytic anemia that responded to increased immune suppression. Following weaning of immune suppression, skin lesions developed that were biopsied, confirming GvHD. Due to systemic manifestations he was deemed to have de novo chronic extensive GvHD. Treatment included steroids, mycophenylate and ultimately extracorporeal photopheresis. Bronchoscopy with bronchoalveolar lavage performed at 6 months post HSCT for nocturnal hypoxia revealed an increased leukocyte count, though no pathogens were isolated (CMV, PCP and aspergillus). Repeat bronchoscopy at 9 months showed CMV growth in lavage fluid, and ganciclovir therapy was started. After 1 month of anti-viral therapy, a repeat bronchoscopy was performed and CMV was no longer detected. At 12 months post HSCT an increased oxygen requirement was noted. CT scan revealed a saddle pulmonary embolism, which cleared after 2 months of enoxaparin. During this time he required escalation of respiratory support, including Bilevel positive airway pressure. Fifteen months post HSCT he developed a pneumo-mediastinum followed by profound hypoxia. He declined mechanical ventilation and died soon afterwards.
Postmortem examination of the lungs grossly revealed bilateral apical pulmonary blebs (Figure 1a) . Histologic sections of the lungs demonstrated diffuse subpleural (Figure 1b) and patchy interstitial fibrosis (Figure 1c ) with pneumocyte hypertrophy and numerous intra-alveolar foamy macrophages. Superimposed acute lung injury with eosinophilic intra-alveolar hyaline membranes (diffuse alveolar damage) was also present (Figure 1d ). These findings are consistent with those previously described in lung tissue from DC subjects, which may also include a heterogeneous appearance due to alternating areas of normal lung, patchy interstitial inflammation, dense collagen deposition and honeycomb changes. GvHD usually has findings of intrabronchiolar T cells, apoptosis and perivenulitis. 9 Finally, several histologic features of the chronic phase of radiation-induced injury overlapped with that of our patient, including interstitial fibrosis and accumulation of foamy macrophages in pulmonary arteries and veins. 10 With informed consent (UAB IRB#F130523005), lung fibroblasts were isolated from remaining tissue, then grown simultaneously with idiopathic pulmonary fibrosis (IPF) lung fibroblasts (provided through UAB Tissue Procurement) and normal lung fibroblasts (obtained through American Type Culture Collection, CCD-19Lu). Cells were routinely passaged when reaching 70-80% confluency and were maintained at low (1%) oxygen environment with 5% CO 2 to enhance growth. Proliferation was assessed by counting cells at each passage to calculate population doubling (PD) using the following formula: PD = (log(N/X))/log2, where N = final count number and X = initial cell count. Levels of reactive oxidative stress (ROS) were determined by FACS analysis of the mean fluorescent intensity (MFI) for dichlorofluorescein (DCF, Sigma), as previously described. 5 Cell growth kinetics are noted in Figure 2 , with control lung fibroblasts maintaining log-phase growth for 50 days in continuous culture. In contrast, DC and IPF lung fibroblasts showed slower cell growth, plateauing after 3 weeks. Cells maintained viability but did not show significant expansion from day 20 to day 50 (Figure 2a) . By day 40, DC fibroblasts underwent significantly fewer population doublings relative to normal lung fibroblasts (Figure 2b ). Examination of oxidative stress by DCF staining demonstrated a timedependent increase in ROS in fibroblasts from DC and IPF patients, relative to control cells (Figure 2c ). Of note, the pattern of increased ROS over time was consistent with the growth kinetics, likely as a consequence of cells reaching their near senescent state.
DC is often associated with pulmonary complications post-HSCT. 6, 11 It is noteworthy that the declines in PFT were also noted in our patient several years prior to HSCT. Controversy exists regarding onset of pulmonary fibrosis in DC, with some investigators believing this is a late finding occurring in older adult DC patients, while others have advocated for early routine PFT in children. 12 Genotype/phenotype correlations exist with regard to marrow failure in DC, with dyskerin mutation patients usually developing earlier onset cytopenia, 1 and studies are ongoing to determine if this also exists with regard to pulmonary disease. Due to pulmonary fibrosis risk in DC, HSCT preparative regimens have attempted to minimize secondary damage to lung tissue. HSCT preparative regimens lacking radiation appear to have fewer pulmonary complications. 13 While the preparative regimen used in our patient is considered to be RIC, it nonetheless contains radiation. Of note, we previously demonstrated DNA cross linkers, including ionizing radiation and epipodophyllotoxins, aberrantly upregulate the p53 DNA damage response, increase levels of ROS and induce cell death in a variety of DC somatic cells. 1, 5 The current analysis of DC pulmonary fibroblasts is the first report to study the molecular consequences of short telomeres in this cell type. The findings of poor proliferation and premature senescence, in addition to increased ROS, are consistent with our previous reports studying somatic cells from DC subjects. Others have examined pulmonary fibroblasts from IPF patients. The pathogenesis of IPF, a progressive interstitial lung disease with a fatal prognosis, remains poorly understood. Recent evidence suggests oxidative stress as a key player in the establishment/progression of lung fibrosis in animal models and possibly in human IPF. 14 Of note, the finding of increased ROS seen only in later, not earlier passages, is consistent with our previous observations in DC skin fibroblasts, perhaps due to cells entry into senescence and an inability to properly regulate antioxidant responses. 15 Understandably, one of the limitations of this study was that DC pulmonary fibroblasts were obtained post HSCT following development of several complications. Thus, it is not possible to completely ascertain whether our observations of increased ROS and proliferative defects in DC pulmonary fibroblasts are intrinsic or a consequence of various insults, including the RIC regimen, GVHD, CMV, pulmonary embolism or long lasting oxygen support with positive airway pressure. While collection of pulmonary tissue pre-HSCT could help address this issue, inherent difficulties and morbidity exist with tissue procurement.
In conclusion, pulmonary complications are frequent in DC patients and can be seen early in the course of the disease. While HSCT can be curative for the hematologic abnormalities associated with DC, underlying lung pathology, likely a consequence of telomere-mediated molecular defects, continues to limit the effectiveness of this therapy. Future studies employing minimally to completely non-ablative regimens may prove beneficial by limiting cellular DNA damage and oxidative stress in DC target organs.
